NDUFS2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: NDUFS2

NCBI ID: G4720

NDUFS2

NDUFS2: A Potential Drug Target and Biomarker for Various Diseases

Native Domain-Driven Unit-Based Splitting (NDUFS2) is a splice variant gene that is located on chromosome 6p21.2. It is a key regulator of microRNA (miRNA) expression and has been implicated in a variety of cellular processes, including cell growth , differentiation, and apoptosis.

NDUFS2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions and interactions with other genes have been extensively studied, and a number of potential therapeutic approaches have been proposed.

One of the key functions of NDUFS2 is its role in regulating miRNA expression. MiRNA is a type of non-coding RNA molecule whose function is to regulate gene expression and control physiological processes such as cell cycle, growth and apoptosis. NDUFS2 binds to miRNA molecules and controls their stability, localization and degradation, thereby affecting the balance of intracellular miRNA expression.

The miRNA binding site (conserved region) of NDUFS2 is considered a therapeutic target. By regulating miRNA expression on NDUFS2, it can have an impact on a variety of diseases, including cancer, neurodegenerative diseases, and immune diseases. For example, some studies have shown that the miRNA binding site of NDUFS2 can be used to treat neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. In these diseases, abnormal expression of miRNA may be related to nerve cell death and damage. Therefore, by regulating the expression of NDUFS2 miRNA, a new therapeutic method may be provided.

In addition, NDUFS2 is also closely related to apoptosis. Apoptosis is an important form of cell death that can clear damaged cells and tissues, thereby maintaining the homeostasis of tissues and organs. The activity of NDUFS2 may be related to the regulation of apoptosis, therefore, it is one of the important genes controlling apoptosis.

The miRNA binding site of NDUFS2 can also be used to treat other diseases, including immune diseases. Immune diseases are a complex class of diseases, including autoimmune diseases, inflammation and tumors. The miRNA binding site of NDUFS2 can regulate the differentiation and function of immune cells, thereby affecting the immune response. Therefore, by regulating the expression of NDUFS2 miRNA, it is possible to provide a new treatment method for immune diseases.

NDUFS2 is an important gene that can be used as a drug target and biomarker. By regulating the expression of NDUFS2 miRNA, it can affect a variety of diseases, including cancer, neurodegenerative diseases and immune diseases. Future research will continue to further investigate the molecular mechanism of NDUFS2 and explore its potential as a drug target or biomarker.

Protein Name: NADH:ubiquinone Oxidoreductase Core Subunit S2

Functions: Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:30922174, PubMed:22036843). Essential for the catalytic activity of complex I (PubMed:30922174, PubMed:22036843). Essential for the assembly of complex I (By similarity). Redox-sensitive, critical component of the oxygen-sensing pathway in the pulmonary vasculature which plays a key role in acute pulmonary oxygen-sensing and hypoxic pulmonary vasoconstriction (PubMed:30922174). Plays an important role in carotid body sensing of hypoxia (By similarity). Essential for glia-like neural stem and progenitor cell proliferation, differentiation and subsequent oligodendrocyte or neuronal maturation (By similarity)

The "NDUFS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets